摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate | 921616-50-4

中文名称
——
中文别名
——
英文名称
phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate
英文别名
benzyl 4-[4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxyphenyl]-3-oxopiperazine-1-carboxylate
phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate化学式
CAS
921616-50-4
化学式
C28H35N3O6
mdl
——
分子量
509.602
InChiKey
DKBKTWJSUHUMRY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    702.5±60.0 °C(Predicted)
  • 密度:
    1.235±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    37
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    88.6
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate乙酸乙酯 、 Brine 作用下, 以 trifluoracetic acid-dichloromethane 为溶剂, 反应 1.0h, 以to give the title compound (812 mg)的产率得到phenylmethyl 3-oxo-4-[4-(4-piperidinyloxy)phenyl]-1-piperazinecarboxylate
    参考文献:
    名称:
    Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists
    摘要:
    本发明涉及式(I)的化合物或其盐和溶剂化物、其制备方法、含有它们的组合物以及它们在治疗各种疾病(如过敏性鼻炎)中的应用,其中R1和R2如规范中所定义。
    公开号:
    US20080275027A1
  • 作为产物:
    描述:
    4-Cbz-2-哌嗪酮tert-butyl 4-(4-iodophenoxy)piperidine-1-carboxylatepotassium phosphatecopper(l) iodideN,N'-二甲基乙二胺 作用下, 以 1,4-二氧六环 为溶剂, 反应 24.0h, 以53%的产率得到phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate
    参考文献:
    名称:
    4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H3 Receptor Antagonists
    摘要:
    A series of ketopiperazines were prepared and evaluated for their activity as histamine H-3 antagonists. From investigation of the tertiary basic center in the aminopropyloxyphenyl template, the 2(R)-methylpyrrolidine was identified as the most potent amine. In the more rigid piperidineoxyphenyl template the N-cyclobutyl group was the most potent amine. The 4-fluorobenzyol, 4-cyanobenzoyl, and 2,4-difluorobenzoyl groups provided good pharmacokinetic profiles for the various amides. The PSA and log D values of these compounds suggested low brain penetration. The compounds had very high selectivity over other receptors and did not inhibit hepatic cytochrome P450, indicating low drug-drug interaction potential. Compound 22i was identified as the best compound of this series based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties.
    DOI:
    10.1021/jm0708228
点击查看最新优质反应信息

文献信息

  • Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists
    申请人:Ancliff Rachael Ann
    公开号:US20080275027A1
    公开(公告)日:2008-11-06
    The invention relates to compounds of formula (I) or salts and solvates thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis: wherein R 1 and R 2 are as defined in the specification.
    本发明涉及式(I)的化合物或其盐和溶剂化物、其制备方法、含有它们的组合物以及它们在治疗各种疾病(如过敏性鼻炎)中的应用,其中R1和R2如规范中所定义。
  • WO2007/9741
    申请人:——
    公开号:——
    公开(公告)日:——
  • PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS
    申请人:GLAXO GROUP LIMITED
    公开号:EP1906964A1
    公开(公告)日:2008-04-09
  • [EN] PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS<br/>[FR] DERIVES DE PIPERAZINONE UTILES COMME ANTAGONISTES ET/OU AGONISTES INVERSES DES RECEPTEURS HISTAMINIQUES H3
    申请人:GLAXO GROUP LTD
    公开号:WO2007009741A1
    公开(公告)日:2007-01-25
    [EN] The invention relates to compounds of formula (I) or salts and solvates thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis, wherein R1 and R2 are as defined in the specification.
    [FR] L'invention concerne des composés représentés par la formule générale (I) ou des sels ou des solvates de ces composés, des procédés destinés à la préparation de ces composés, des compositions contenant ces composés et leur application dans le traitement de divers troubles, tels que la rhinite allergique. Dans la formule générale (I), R1 et R2 désignent des éléments définis dans la description.
  • 4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H<sub>3</sub> Receptor Antagonists
    作者:Panayiotis A. Procopiou、Rachael A. Ancliff、Mark J. Bamford、Christopher Browning、Helen Connor、Susannah Davies、Yvonne C. Fogden、Simon T. Hodgson、Duncan S. Holmes、Brian E. Looker、Karen M. L. Morriss、Christopher A. Parr、Elizabeth A. Pickup、Sanjeet S. Sehmi、Gemma V. White、Clarissa J. Watts、David M. Wilson、Michael D. Woodrow
    DOI:10.1021/jm0708228
    日期:2007.12.27
    A series of ketopiperazines were prepared and evaluated for their activity as histamine H-3 antagonists. From investigation of the tertiary basic center in the aminopropyloxyphenyl template, the 2(R)-methylpyrrolidine was identified as the most potent amine. In the more rigid piperidineoxyphenyl template the N-cyclobutyl group was the most potent amine. The 4-fluorobenzyol, 4-cyanobenzoyl, and 2,4-difluorobenzoyl groups provided good pharmacokinetic profiles for the various amides. The PSA and log D values of these compounds suggested low brain penetration. The compounds had very high selectivity over other receptors and did not inhibit hepatic cytochrome P450, indicating low drug-drug interaction potential. Compound 22i was identified as the best compound of this series based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties.
查看更多